DEPARTMENT OF THE ARMY
HEADQUARTERS U.S. ARMY MEDICAL DEPARTMENT ACTIVITY
FORT KNOX, KENTUCKY 40121-5520

K-8

REPLY TO
ATTENTION OF

MCXM-PMR

08 December 2008

MEMORANDUM THRU COMMANDER, Walter Reed Army Medical Center (AMC)
ATTN: Chief, Health Physics Office (COL Mark Melanson), Washington DC 20307-5001

FOR U.S. Nuclear Regulatory Commission, Division of Nuclear Materials Safety, Region I 475 Allendale Road, King of Prussia, PA 19406

SUBJECT: NRC License Amendment – Request for New Authorized User

1. This is to notify you that our Radiation Control Committee has approved CPT Eva Smietana, M.D., as an Authorized User for medical use under 10 CFR Parts 35.100, 35.200, 35.300, and 31.11. Dr. Smietana has been working under the supervision of COL Kevin Reilly, M.D., an authorized user, IAW with 10 CFR Part 35.25, since July of 2008. Our Radiation Control Committee approval memorandum, Dr. Smietana's credentials and applicable documentation are enclosed with this memorandum. We request the addition of Dr. Smietana to our USNRC Byproduct Material License (License # 16-03657-01). 03001748

2. This is to notify you that our Radiation Control Committee has also approved Michael M. Tate, M.D., as an Authorized User for medical use under 10 CFR Parts 35.100, 35.200, 35.300, 35.500 and 31.11. Dr. Tate is under a long-term contract with our hospital and is currently the radiation safety officer and an authorized user on USNRC license 13-12367-01. Our Radiation Control Committee approval memorandum and a copy of the USNRC aforementioned license are enclosed with this memorandum. We request the addition of Dr. Tate to our USNRC Byproduct Material License (License # 16-03657-01).

3. The point of contact for this memorandum is the undersigned at (502) 624-0589.

SARAH M. SUBLETT
1LT, MS
Chief, Health Physics/Radiation Protection

6 Encls

1. RCC Approval

REC'D IN LAT 12/11/08

143066
NMSS/RGN1 MATERIALS-002

2. Certificate in Diagnostic Radiology
3. Letter of Diagnostic Radiology Certification
4. Medical School Diploma
5. USNRC Form 313A (Preceptor Statement)
6. USNRC License 13-12367-01

DEPARTMENT OF THE ARMY
HEADQUARTERS, U.S. ARMY MEDICAL DEPARTMENT ACTIVITY
FORT KNOX, KENTUCKY 40121-5520

MCXM-PMR

18 November 2008

MEMORANDUM FOR RCC

SUBJECT: RCC Approval of CPT Eva Smietana, M.D. and Michael M. Tate, M.D. as Authorized Users for Medical Use on IACH's NRC License

1. CPT Eva Smietana, M.D. is currently assigned to IACH's Department of Radiology and Michael M. Tate, M.D. is under contract to IACH's Department of Radiology and they are requesting RCC approval as Authorized Users for medical use. There approval and addition to IACH's US NRC License will authorize them to practice Nuclear Medicine studies using radiopharmaceuticals and radioactive materials covered under 10 CFR Parts 35.100, 35.200, 35.300, 35.500 and 31.11 for uptake, dilution, excretion studies and diagnostic imaging purposes on the MEDDAC NRC License and DARA. Their credentials are attached. For CPT Smietana it is her letter of Nuclear Medicine Training Verification, letter of Diagnostic Radiology Certification, Medical School Diploma, and USNRC Form 313A (Preceptor Statement) and for Dr. Tate it is a copy of the USNRC license that he is currently on.

2. Please indicate your approval or disapproval by signing in the appropriate column below:

	Approval	Disapproval
LTC Raney, DCCS, RCC Chairperson		
LTC Reilly, Chief, NMS and Radiology		
MAJ Gardiner, Chief, Preventive Medicine		
MAJ McCann, Representative DON		
1LT Sublett, Health Physics/RPO		

3. Upon RCC approval, an amendment request will be submitted to the US Nuclear Regulatory Commission.

4. POC for this memorandum is the undersigned at (502)624-0589.

SARAH M. SUBLETT
1LT, MS
Chief, Health Physics Office

The American Board of Radiology

DIAGNOSTIC RADIOLOGY ■ RADIATION ONCOLOGY ■ RADIOLOGIC PHYSICS

5441 E. Williams Boulevard, Suite 200 Tucson, Arizona 85711-4493 Phone (520) 790-2900 · Fax (520) 790-3200
E-mail: information@theabr.org website: www.theabr.org

June 2, 2008

ABRID 57212 / DR / 13 / 21

Confirmation # 5LAL46F9

Eva Marie Smietana, MD
1826 Kilbourne Pl NW
Washington, DC 20010

Dear Dr. Smietana:

I am pleased to inform you that you passed the oral examination held on May 31 to June 3, 2008. The American Board of Radiology grants you its Certificate in Diagnostic Radiology. This is a ten-year time-limited certificate. In addition, because you received the appropriate training to make you AU-Eligible and passed the NRC-related portions of the nuclear radiology section, you will receive the AU-Eligible designation on your certificate.

The certificate will be sent to the above address in approximately three months from our printer, Jim Henry, Inc. Your name will appear on the certificate as shown above. If you wish your name to appear differently or you have an address change, please notify the Board office in writing by July 02, 2008. Your name and demographic information will be included in a Directory published by the American Board of Medical Specialties. It is your responsibility to notify other local and state or national organizations of your certification.

Important information about your Maintenance of Certification process is enclosed. Please review it and respond as requested.

Personally and on behalf of the Board of Trustees of The American Board of Radiology, I wish to congratulate you for this distinguished achievement. You have accomplished one of the most significant milestones in your career.

Sincerely,

Gary J. Becker, MD

Enclosures

3. Training and Experience for Proposed Authorized User (continued)

b Supervised Work Experience. (continued)

Description of Experience Must Include	Location of Experience/License or Permit Number of Facility	Confirm	Dates of Experience*
Calculating, measuring, and safely preparing patient or human research subject dosages		☐ Yes ☐ No	
Using administrative controls to prevent a medical event involving the use of unsealed byproduct material		☐ Yes ☐ No	
Using procedures to contain spilled byproduct material safely and using proper decontamination procedures		☐ Yes ☐ No	
Administering dosages of radioactive drugs to patients or human research subjects		☐ Yes ☐ No	
Eluting generator systems appropriate for the preparation of radioactive drugs for imaging and localization studies, measuring and testing the eluate for radionuclidic purity and processing the eluate with reagent kits to prepare labeled radioactive drugs		☐ Yes ☐ No	

Supervising Individual — License/Permit Number listing supervising individual as an authorized user

Supervisor meets the requirements below, or equivalent Agreement State requirements *(check one)*.

35.190 | 35.290 | 35.390 | 35.390 + generator experience in 35.290(c)(1)(ii)(G)

c For 35.590 only, provide documentation of training on use of the device.

Device	Type of Training	Location and Dates

d. For 35.500 uses only, stop here. For 35.100 and 35.200 uses skip to and complete Part II Preceptor Attestation

[redacted]

NRC FORM 313A (AUD) U.S. NUCLEAR REGULATORY COMMISSION

AUTHORIZED USER TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (continued)

PART II – PRECEPTOR ATTESTATION

Note: This part must be completed by the individual's preceptor. The preceptor does not have to be the supervising individual as long as the preceptor provides, directs, or verifies training and experience required. If more than one preceptor is necessary to document experience obtain a separate preceptor statement from each. (Not required to meet training requirements in 35.590)

By checking the boxes below, the preceptor is attesting that the individual has knowledge to fulfill the duties of the position sought and not attesting to the individual's "general clinical competency."

First Section
Check one of the following for each use requested:

For 35.190

Board Certification

✓ I attest that **Eva M. Smietana, MD** (Name of Proposed Authorized User) has satisfactorily completed the requirements in 10 CFR 35.190(a)(1) and has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under 10 CFR 35.100

OR

Training and Experience

I attest that _____ (Name of Proposed Authorized User) has satisfactorily completed the 60 hours of training and experience, including a minimum of 8 hours of classroom and laboratory training, required by 10 CFR 35.190(c)(1), and has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under 10 CFR 35.100

For 35.290

Board Certification

✓ I attest that **Eva M. Smietana, MD** (Name of Proposed Authorized User) has satisfactorily completed the requirements in 10 CFR 35.290(a)(1) and has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under 10 CFR 35.100 and 35.200.

OR

Training and Experience

I attest that _____ (Name of Proposed Authorized User) has satisfactorily completed the 700 hours of training and experience, including a minimum of 80 hours of classroom and laboratory training, required by 10 CFR 35.290(c)(1), and has achieved a level of competency sufficient to function independently as an authorized user for the medical uses authorized under 10 CFR 35.100 and 35.200.

Second Section
Complete the following for preceptor attestation and signature:

✓ I meet the requirements below, or equivalent Agreement State requirements, as an authorized user for:

35.190 35.290 35.390 ✓ 35.390 + generator experience

Name of Preceptor	Signature	Telephone Number	Date
Sidney R. Hinds II, MD		(202) 782-5299	12/05/2008

License/Permit Number/Facility Name

License #08-01738-02 / Walter Reed Army Medical Center

[redacted]

NRC FORM 313A (AUT) U.S. NUCLEAR REGULATORY COMMISSION

AUTHORIZED USER TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (for uses defined under 35.300) [10 CFR 35.390, 35.392, 35.394, and 35.396]

APPROVED BY OMB: NO. 3150-0120
EXPIRES: 10/31/2008

Name of Proposed Authorized User	State or Territory Where Licensed
Eva M. Smietana, MD	Kentucky

Requested Authorization(s) *(check all that apply)*

✓ 35.300 Use of unsealed byproduct material for which a written directive is required

OR

35.300 Oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)

35.300 Oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries)

35.300 Parenteral administration of any beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required

35.300 Parenteral administration of any other radionuclide for which a written directive is required

PART I -- TRAINING AND EXPERIENCE
(Select one of the three methods below)

Training and Experience, including board certification, must have been obtained within the 7 years preceding the date of application or the individual must have related continuing education and experience since the required training and experience was completed. Provide dates, duration, and description of continuing education and experience related to the uses checked above.

✓ 1. **Board Certification**

a. Provide a copy of the board certification

b. For 35.390, provide documentation on supervised clinical case experience. The table in section 3.c. may be used to document this experience

c. For 35.396, provide documentation on classroom and laboratory training, supervised work experience, and supervised clinical case experience. The tables in sections 3.a., 3.b., and 3.c. may be used to document this experience

d. Skip to and complete Part II Preceptor Attestation

2. **Current 35.300, 35.400, or 35.600 Authorized User Seeking Additional Authorization**

a. Authorized User on Materials License under the requirements below or equivalent Agreement State requirements *(check all that apply)*

35.390 35.392 35.394 35.490 35.690

b. If currently authorized for a subset of clinical uses under 35.300, provide documentation on additional required supervised case experience. The table in section 3.c. may be used to document this experience. Also provide completed Part II Preceptor Attestation.

c. If currently authorized under 35.490 or 35.690 and requesting authorization for 35.396, provide documentation on classroom and laboratory training, supervised work experience, and supervised clinical case experience. The tables in sections 3.a., 3.b., and 3.c. may be used to document this experience. Also provide completed Part II Preceptor Attestation

[redacted]

AUTHORIZED USER TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (continued)

3. **Training and Experience for Proposed Authorized User**

a Classroom and Laboratory Training 35.390 35.392 35.394 35.396

Description of Training	Location of Training	Clock Hours	Dates of Training*
Radiation physics and instrumentation			
Radiation protection			
Mathematics pertaining to the use and measurement of radioactivity			
Chemistry of byproduct material for medical use			
Radiation biology			
Total Hours of Training:			

b Supervised Work Experience 35.390 35.392 35.394 35.396

If more than one supervising individual is necessary to document supervised training, provide multiple copies of this page.

Supervised Work Experience

Description of Experience Must Include	Location of Experience/License or Permit Number of Facility	**Total Hours of Experience:** Confirm	Dates of Experience*
Ordering, receiving, and unpacking radioactive materials safely and performing the related radiation surveys		Yes / No	
Performing quality control procedures on instruments used to determine the activity of dosages and performing checks for proper operation of survey meters		Yes / No	
Calculating, measuring, and safely preparing patient or human research subject dosages		Yes / No	
Using administrative controls to prevent a medical event involving the use of unsealed byproduct material		Yes / No	
Using procedures to contain spilled byproduct material safely and using proper decontamination procedures		Yes / No	

[redacted]

AUTHORIZED USER TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (continued)

3. Training and Experience for Proposed Authorized User (continued)

b. Supervised Work Experience (continued)

Supervising Individual

License/Permit Number listing supervising individual as an authorized user

Supervising individual meets the requirements below, or equivalent Agreement State requirements *(check all that apply)***

35.390 With experience administering dosages of:

35.392 Oral NaI-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)

35.394 Oral NaI-131 in quantities greater than 1.22 gigabecquerels (33 millicuries)

35.396 Parenteral administration of beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV requiring a written directive is required

Parenteral administration of any other radionuclide requiring a written directive

** Supervising Authorized User must have experience in administering dosages in the same dosage category or categories as the individual requesting authorized user status.

c. Supervised Clinical Case Experience

If more than one supervising individual is necessary to document supervised work experience, provide multiple copies of this page.

Description of Experience	Number of Cases Involving Personal Participation	Location of Experience/License or Permit Number of Facility	Dates of Experience*
Oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)			
Oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries)			
Parenteral administration of any beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required			
Parenteral administration of any other radionuclide for which a written directive is required			

(List radionuclides)

[redacted]

NRC FORM 313A (AUT) U.S. NUCLEAR REGULATORY COMMISSION

AUTHORIZED USER TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (continued)

3. **Training and Experience for Proposed Authorized User** (continued)

c. Supervised Clinical Case Experience (continued)

Supervising Individual	License/Permit Number listing supervising individual as an authorized user

Supervising individual meets the requirements below, or equivalent Agreement State requirements *(check all that apply)***

35.390 With experience administering dosages of:

35.392 Oral NaI-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)

35.394 Oral NaI-131 in quantities greater than 1.22 gigabecquerels (33 millicuries)

35.396 Parenteral administration of beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV requiring a written directive is required

Parenteral administration of any other radionuclide requiring a written directive

** Supervising Authorized User must have experience in administering dosages in the same dosage category or categories as the individual requesting authorized user status

d. Provide completed Part II Preceptor Attestation

PART II – PRECEPTOR ATTESTATION

Note This part must be completed by the individual's preceptor. The preceptor does not have to be the supervising individual as long as the preceptor provides, directs, or verifies training and experience required. If more than one preceptor is necessary to document experience, obtain a separate preceptor statement from each.

By checking the boxes below, the preceptor is attesting that the individual has knowledge to fulfill the duties of the position sought and not attesting to the individual's "general clinical competency."

First Section
Check one of the following for each requested authorization:

For 35.390:

Board Certification

I attest that **Eva M. Smietana, MD** has satisfactorily completed the training and experience
Name of Proposed Authorized User

requirements in 35.390(a)(1).

OR

Training and Experience

I attest that _____ has satisfactorily completed the 700 hours of training
Name of Proposed Authorized User

and experience, including a minimum of 200 hours of classroom and laboratory training, as required by 10 CFR 35.390 (b)(1).

[redacted]

AUTHORIZED USER TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (continued)

Preceptor Attestation (continued)

First Section (continued)

For 35.392 (Identical Attestation Statement Regardless of Training and Experience Pathway):

I attest that _____ has satisfactorily completed the 80 hours of classroom
Name of Proposed Authorized User

and laboratory training, as required by 10 CFR 35.392(c)(1), and the supervised work and clinical case experience required in 35.392(c)(2).

For 35.394 (Identical Attestation Statement Regardless of Training and Experience Pathway):

I attest that _____ has satisfactorily completed the 80 hours of classroom
Name of Proposed Authorized User

and laboratory training, as required by 10 CFR 35.394 (c)(1), and the supervised work and clinical case experience required in 35.394(c)(2).

Second Section

I attest that _____ has satisfactorily completed the required clinical case
Name of Proposed Authorized User

experience required in 35.390(b)(1)(ii)G listed below:

Oral NaI-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)

Oral NaI-131 in quantities greater than 1.22 gigabecquerels (33 millicuries)

Parenteral administration of beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV requiring a written directive is required

Parenteral administration of any other radionuclide requiring a written directive

---

Third Section

I attest that _____ has satisfactorily achieved a level of competency to
Name of Proposed Authorized User

function independently as an authorized user for:

Oral NaI-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)

Oral NaI-131 in quantities greater than 1.22 gigabecquerels (33 millicuries)

Parenteral administration of beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV requiring a written directive is required

Parenteral administration of any other radionuclide requiring a written directive

[redacted]

NRC FORM 313A (AUT) U.S. NUCLEAR REGULATORY COMMISSION

AUTHORIZED USER TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (continued)

Fourth Section

For 35.396:

Current 35.490 or 35.690 authorized user:

I attest that _____ is an authorized user under 10 CFR 35.490 or 35.690
Name of Proposed Authorized User

or equivalent Agreement State requirements, has satisfactorily completed the 80 hours of classroom and laboratory training, as required by 10 CFR 35.396 (d)(1), and the supervised work and clinical case experience required by 35.396(d)(2), and has achieved a level of competency sufficient to function independently as an authorized user for

Parenteral administration of any beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required

Parenteral administration of any other radionuclide for which a written directive is required

OR

Board Certification:

I attest that _____ has satisfactorily completed the board certification
Name of Proposed Authorized User

requirements of 35.396(c), has satisfactorily completed the 80 hours of classroom and laboratory training required by 10 CFR 35.396 (d)(1) and the supervised work and clinical case experience required by 35.396(d)(2), and has achieved a level of competency sufficient to function independently as an authorized user for

Parenteral administration of any beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV for which a written directive is required

Parenteral adminstration of any other radionuclide for which a written directive is required

---

Fifth Section

Complete the following for preceptor attestation and signature:

✓ I meet the requirements below, or equivalent Agreement State requirements, as an authorized user for

✓ 35.390 ✓ 35.392 ✓ 35.394 ✓ 35.396

✓ I have experience administering dosages in the following categories for which the proposed Authorized User is requesting authorization

✓ Oral NaI-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries)

✓ Oral NaI-131 in quantities greater than 1.22 gigabecquerels (33 millicuries)

✓ Parenteral administration of beta-emitter, or photon-emitting radionuclide with a photon energy less than 150 keV requiring a written directive is required

✓ Parenteral administration of any other radionuclide requiring a written directive

Name of Preceptor	Signature	Telephone Number	Date
Sidney R. Hinds II, MD		(202) 782-5299	12/05/2008

License/Permit Number/Facility Name

License #08-01738-02 / Walter Reed Army Medical Center

[redacted]

NRC FORM 374 301-6811 U.S. NUCLEAR REGULATORY COMMISSION PAGE 1 OF 5 PAGES
Amendment No. 32

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to possess and transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with letter dated February 5, 2007,
Clark Memorial Hospital	3. License number 13-12367-01 is amended in its entirety as follows:
1220 Missouri Avenue	4. Expiration date October 31, 2014
Jeffersonville, IN 47130	5. Docket No. 030-01658 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. Not to exceed 1 curie
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed sources (Bard Brachytherapy Model No. STM-1251 and Theragenics Model No. 200)	D. Not to exceed 2 curies
E. Any byproduct material permitted by 10 CFR 31.11	E. Prepackaged kits	E. As needed
F. Strontium-90	F. Sealed source (Tracerlab Model RA-2A)	F. One source not to exceed 100 millicuries

Authorized Use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging or localization study permitted by 10 CFR 35.200

C. Any therapy procedure permitted by 10 CFR 35.300

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-12367-01

Docket or Reference Number
030-01658

Amendment No. 32

D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

E. In vitro studies.

F. For possession only, incident to disposal.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 1220 Missouri Avenue, Jeffersonville, Indiana.

11. Radiation Safety Officer Michael M Tate, M.D

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical uses:

Authorized Users	Material and Use
H David Heideman, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
David R. Cannon, M D.	10 CFR 35.100, 35.200 and 31.11.
Mohammed Hussain, M.D.	10 CFR 35.100 and 35.200.
Dolph Martel Denny, M D.	10 CFR 35.100 and 35.200.
William R. Fortner, M D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Stephen R. Regan, M D.	10 CFR 35.100, 35 200, 35.300 and 31.11.
Edsel S. Reed, M D.	10 CFR 35 100, 35 200, 35.300 and 31.11.
Anthony Duncan, M D.	10 CFR 35.100, 35.200, 35.300 and 31.11
Kelly J Colomb, M D.	10 CFR 35 100, 35.200, 35.300 and 31.11

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-12367-01

Docket or Reference Number
030-01658

Amendment No. 32

Bapineedu Gondi, M.D.	10 CFR 35.100 and 35.200.
Gary Yurow, M.D.	10 CFR 35.100 and 35.200.
Stephen J. Matthews, M.D.	10 CFR 35.100, 35.200 and 35.300 excluding thyroid carcinoma therapy.
Michael M. Tate, M.D.	10 CFR 35.100, 35.200, 35.300 and 31.11.
Koduvathara James, M.D.	10 CFR 35.100 and 35.200.
Carl E. Dillman, M.D.	10 CFR 35.100 and 35.200.
D. Mark Bickers, M.D.	10 CFR 35.100 and 35.200.
Wayne Shugoll, M.D.	10 CFR 35.100 and 35.200.
Armand Rothschild, M.D.	10 CFR 35.100 and 35.200.
Gurbachan Sohi, M.D.	10 CFR 35.100 and 35.200.
Sohail Ikram, M.D.	10 CFR 35.100 and 35.200.
Thomas Matthew Sweat, M.D.	10 CFR 35.100 and 35.200.
William J. Schoen, M.D.	10 CFR 35.100 and 35.200.
John Terrence Kenny, M.D.	10 CFR 35.100 and 35.200.
Frederick Albrink, M.D.	10 CFR 35.300 and materials listed in Subitems 6.D.
Zaka Ur Rahman, M.D.	10 CFR 35.100 and 35.200.
Craig S. Kamen, M.D.	10 CFR 35.100, 35.200 and 35.300.
F. Baby Jose, M.D.	For materials listed in Subitem 6.D.
Mark Cornett, M.D.	For materials listed in Subitem 6.D.
Mark Jones, M.D.	For materials listed in Subitem 6.D.
Zulfiquar Bhatti, M.D.	10 CFR 35.100 and 35.200.
Brian Worm, M.D.	10 CFR 35.100, 35.200 and 35.300.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-12367-01

Docket or Reference Number
030-01658

Amendment No. 32

Ali Nawab Rizvi, M.D	10 CFR 35.100 and 35.200.
Geoffrey Peters, M.D	10 CFR 35.100 and 35.200.
Srinivasarao Manchikalapudi, M.D.	10 CFR 35.100 and 35.200.
Kendall Goldschmidt, M.D	10 CFR 35.100 and 35.200 and 35.300.
Christopher J. Day, M.D	10 CFR 35.100 and 35.200 and 35.300 (excluding iodine-131 for thyroid carcinoma).
Kevin E. Burton, M.D.	10 CFR 35.100 and 35.200.
Thomas C. Passo, M.D.	10 CFR 35.100 and 35.200.
Naresh Solankhi, M.D.	10 CFR 35.100 and 35.200.
Naveen Devabhaktuni, M.D.	10 CFR 35.100 and 35.200.
Mitchell Jay Kline, M.D.	10 CFR 35.100 and 35.200.
Jerome Schrodt, M.D.	10 CFR 35.100, 35.200 and oral administration of sodium iodide-131 in quantities less than or equal to 33 millicuries.
Richard Eickler, M.D.	10 CFR 35.100 and 35.200.
Kevin P. Serey, M.D.	10 CFR 35.100, 35.200 and 35.300 limited to oral administration of sodium iodide-131.
David P. Musich, M.D.	10 CFR 35.300, 35.400 and 31.11.

The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
13-12367-01

Docket or Reference Number
030-01658

Amendment No. 32

12. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated April 22, 2004, and,

B. Letter received October 21, 2004.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date APR 16 2007

By _____
Toye L. Simmons
Materials Licensing Branch
Region III